Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey

British Journal of Pharmacology

Volumn 175, Issue 7, 2018, Pages 1054-1065

  Hohlbaum, Andreas M ^a   Gille, Hendrik ^a   Trentmann, Stefan ^a   Kolodziejczyk, Maria ^a   Rattenstetter, Barbara ^a   Laarakkers, Coby M ^b,c   Katzmann, Galina ^a   Christian, Hans Jürgen ^a   Andersen, Nicole ^a   Allersdorfer, Andrea ^a   Olwill, Shane A ^a   Meibohm, Bernd ^d   Audoly, Laurent P ^a   Swinkels, Dorine W ^b,c   van Swelm, Rachel P L ^b,c  

^a Pieris Pharmaceuticals GmbH   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Hepcidinanalysiscom   (Netherlands)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPCIDIN; IRON; LIPOCALIN; MACROGOL; PEPTIDE HORMONE ANTAGONIST; PRS 080; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; HORMONE BLOOD LEVEL; HUMAN; IN VIVO STUDY; IRON BLOOD LEVEL; IRON KINETICS; MACACA FASCICULARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; FEMALE; MALE;

ANIMALS; FEMALE; HEPCIDINS; IRON; MACACA FASCICULARIS; MALE; MODELS, BIOLOGICAL;

EID: 85042384625     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14143     Document Type: Article

References (50)

1. Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD et al. (2017). The Concise Guide to PHARMACOLOGY 2017/18: Transporters. Br J Pharmacol 174: S360–S446.
2. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L et al. (2009). BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. NatGenet 41: 482–487.
3. Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T et al. (2015). Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 30: 1665–1673.
4. Bishu K, Agarwal R (2006). Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 1 (Suppl 1): S19–S23.
5. Boser P, Seemann D, Liguori MJ, Fan L, Huang L, Hafner M et al. (2015). Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron in rats and cynomolgus monkeys by hepcidin downregulation. AAPS J 17: 930–938.
6. Boyce M, Warrington S, Cortezi B, Zöllner S, Vauleon S, Swinkels DW et al. (2016). Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol 173: 1580–1588.
7. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP et al. (2015). Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 26: 1238–1247.
8. Cooke KS, Hinkle B, Salimi-Moosavi H, Foltz I, King C, Rathanaswami P et al. (2013). A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 122: 3054–3061.
9. Crielaard B, Lammers T, Rivera S (2017). Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov 16: 4.
10. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
11. De Falco L, Sanchez M, Silvestri L, Kannengiesser C, Muckenthaler MU, Iolascon A et al. (2013). Iron refractory iron deficiency anemia. Haematologica 98: 845–853.
12. Fleming RE, Sly WS (2001). Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci U S A 98: 8160–8162.
13. Ganz T, Nemeth E (2009). Iron sequestration and anemia of inflammation. Semin Hematol 46: 387–393.
14. Ganz T, Nemeth E (2011). Hepcidin and disorders of iron metabolism. Annu Rev Med 62: 347–360.
15. Gille H, Hulsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T et al. (2016). Functional characterization of a VEGF-A-targeting anticalin, prototype of a novel therapeutic human protein class. Angiogenesis 19: 79–94.
16. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK (2002). The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10: 1033–1043.
17. Guo W, Bachman E, Li M, Roy CN, Blusztajn J, Wong S et al. (2013). Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell 12: 280–291.
18. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091–D1106.
19. Hohlbaum AM, Jensen K, Allersdorfer A, Baehre A, Bel Aiba RS, Christian J et al. (2011). Exploiting lipocalin biochemistry for the treatment of allergy and asthma: discovery and characterization of an anti-IL-4RA therapeutic. C21. NEW TARGETS FOR ASTHMA THERAPY. American Thoracic Society.
20. Home office (1989). Animals (Scientific Procedures) act 1986, Code of Practice for the housing and care of animals used in scientific procedures. ISBN 0102107890, HC 107 1988–89.
21. Kagan L, Abraham AK, Harrold JM, Mager DE (2010). Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 27: 920–932.
22. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D (2005). Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 106: 1864–1866.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
24. Kim HJ, Eichinger A, Skerra A (2009). High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc 131: 3565–3576.
25. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE et al. (2010). Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 56: 1570–1579.
26. Krzyzanski W, Xiao JJ, Sasu B, Hinkle B, Perez-Ruixo JJ (2016). Pharmacodynamic model of hepcidin regulation of iron homeostasis in cynomolgus monkeys. AAPS J 18: 713–727.
27. Laarakkers CM, Wiegerinck ET, Klaver S, Kolodziejczyk M, Gille H, Hohlbaum AM et al. (2013). Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. PLoS One 8: e75518.
28. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P et al. (2016). Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 89: 28–39.
29. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
30. Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A et al. (2013). First-in-human phase I study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One 8: e83232.
31. Nemeth E (2010). Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010: 750643.
32. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK et al. (2004a). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271–1276.
33. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM et al. (2004b). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090–2093.
34. Ohlson M, Sorensson J, Haraldsson B (2000). Glomerular size and charge selectivity in the rat as revealed by FITC-ficoll and albumin. Am J Physiol Renal Physiol 279: F84–F91.
35. Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A et al. (2013). A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Mol Cancer Ther 12: 2459–2471.
36. Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH (2016). Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90: 1115–1122.
37. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P et al. (2016). Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67: 912–924.
38. Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I et al. (2012). Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab 15: 905–917.
39. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C et al. (2012). Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 125 (991–999): e1.
40. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC (2007). Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 109: 4038–4044.
41. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J et al. (2010). Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115: 3616–3624.
42. Schlehuber S, Beste G, Skerra A (2000). A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J Mol Biol 297: 1105–1120.
43. Schonfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, Hulsmeyer M et al. (2009). An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci USA 106: 8198–8203.
44. Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C et al. (2013). The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 121: 2311–2315.
45. Slotki I, Cabantchik ZI (2015). The labile side of iron supplementation in CKD. J Am Soc Nephrol 26: 2612–2619.
46. Sun CC, Vaja V, Babitt JL, Lin HY (2012). Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. AmJHematol 87: 392–400.
47. van Eijk LT, John AS, Schwoebel F, Summo L, Vauleon S, Zollner S et al. (2014). Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 124: 2643–2646.
48. Weiss G, Goodnough LT (2005). Anemia of chronic disease. NEnglJMed 352: 1011–1023.
49. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY (2008). Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 111: 5195–5204.
50. Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M et al. (2010). Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPSJ 12: 646–657.